Some researches have found that low level of vascular cell adhesion molecule-1 (VCAM-1), E-selectin, angiopoietin 2 (Ang-2) in circulation or carbonic anhydrase 9 (CA9), CD31- microvessel density (CD31-MVD) in tumor tissue can predict beter activity of bevacizumab. This evidence concerns the gene ANGPT2 and neoplasm.